143 related articles for article (PubMed ID: 30829551)
41. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
42. Role of D2 gastrectomy in gastric cancer with clinical para-aortic lymph node metastasis.
Zheng XH; Zhang W; Yang L; Du CX; Li N; Xing GS; Tian YT; Xie YB
World J Gastroenterol; 2019 May; 25(19):2338-2353. PubMed ID: 31148905
[TBL] [Abstract][Full Text] [Related]
43. [Stage IV Gastric Cancer with Positive Peritoneal Washing Cytology or Peritoneal Dissemination Was Successfully Treated with Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy(HIPEC)Followed by Systemic Chemotherapy - A Report of Two Cases].
Yamaguchi T; Murata S; Kaida S; Ohtake R; Takebayashi K; Yamamoto H; Miyake T; Akabori H; Sonoda H; Mori T; Shimizu T; Naka S; Moritani S; Kushima R; Tani M
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1954-1956. PubMed ID: 28133187
[TBL] [Abstract][Full Text] [Related]
44. [Safety and efficacy of intraperitoneal hyperthermic perfusion chemotherapy following laparoscopic palliative resection for gastric cancer patients with peritoneal metastasis].
Xia W; Hu Y; Mou T; Chen T; Yu J; Li G
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Nov; 17(11):1087-91. PubMed ID: 25421766
[TBL] [Abstract][Full Text] [Related]
45. [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Mihara K; Yamashiro N; Nishiya S; Kemmochi T; Ito Y; Egawa T; Nagashima A
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2358-60. PubMed ID: 25731522
[TBL] [Abstract][Full Text] [Related]
46. Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer.
Samel S; Singal A; Becker H; Post S
Eur J Surg Oncol; 2000 Apr; 26(3):222-6. PubMed ID: 10753533
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
48. Feasibility study of postoperative intraperitoneal hyperthermochemotherapy by radiofrequency capacitive heating system for advanced gastric cancer with peritoneal seeding.
Mochiki E; Shioya M; Sakurai H; Andoh H; Ohno T; Aihara R; Asao T; Kuwano H
Int J Hyperthermia; 2007 Sep; 23(6):493-500. PubMed ID: 17952763
[TBL] [Abstract][Full Text] [Related]
49. [Hepatic Resection of Multiple Liver Metastases from Gastric Cancer after Molecular Targeted Chemotherapy(S-1 plus Cisplatin plus Trastuzumab)].
Kim Y; Hosoda Y; Nishino M; Okano M; Kawada J; Yamasaki M; Nagai K; Yasui M; Okuyama M; Tsujinaka T
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1635-7. PubMed ID: 26805121
[TBL] [Abstract][Full Text] [Related]
50. Regional but fatal: Intraperitoneal metastasis in gastric cancer.
Wei J; Wu ND; Liu BR
World J Gastroenterol; 2016 Sep; 22(33):7478-85. PubMed ID: 27672270
[TBL] [Abstract][Full Text] [Related]
51. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
Leichman L; Silberman H; Leichman CG; Spears CP; Ray M; Muggia FM; Kiyabu M; Radin R; Laine L; Stain S
J Clin Oncol; 1992 Dec; 10(12):1933-42. PubMed ID: 1453207
[TBL] [Abstract][Full Text] [Related]
52. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
[TBL] [Abstract][Full Text] [Related]
53. A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.
He Q; Ma L; Li Y; Li G
BMC Gastroenterol; 2016 Jan; 16():8. PubMed ID: 26782354
[TBL] [Abstract][Full Text] [Related]
54. Reply to "Peritoneal carcinomatosis in patients with gastric cancer and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy".
Graziosi L; Marino E; Donini A
Am J Surg; 2014 Jul; 208(1):158-9. PubMed ID: 24530090
[No Abstract] [Full Text] [Related]
55. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
56. Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement.
Frasci G; Iaffaioli RV; Comella G; Comella P; Salzano F; Galizia G; Imbriani A; Persico G
Clin Oncol (R Coll Radiol); 1994; 6(6):364-70. PubMed ID: 7873482
[TBL] [Abstract][Full Text] [Related]
57. Neuroendocrine carcinoma of the gastric stump: A case report and literature review.
Ma FH; Xue LY; Chen YT; Xie YB; Zhong YX; Xu Q; Tian YT
World J Gastroenterol; 2018 Jan; 24(4):543-548. PubMed ID: 29398875
[TBL] [Abstract][Full Text] [Related]
58. [Urgent gastrectomy in a patient who developed perforated gastric cancer during preoperative chemotherapy with S-1 plus cisplatin].
Okabe Y; Yajima K; Ishikawa T; Kosugi S; Sakamoto K; Sato Y; Kanda T; Wakai T
Gan To Kagaku Ryoho; 2014 Jan; 41(1):95-8. PubMed ID: 24423960
[TBL] [Abstract][Full Text] [Related]
59. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
Hotopp T
Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
[TBL] [Abstract][Full Text] [Related]
60. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
